Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak

Novo Nordisk, the Danish pharmaceutical giant behind the popular diabetes drug Ozempic, is facing a major setback as its stock price plummeted by 70% from its peak, prompting Deutsche Bank to downgrade it to a "sell" recommendation. Despite the company's previous success, this downgrade reflects growing concerns about its future performance and market position. Analysts suggest that the shift indicates a potential loss of investor confidence, which could have broader implications for the pharmaceutical sector and the company's ability to innovate and compete globally.